Dataset Information

Early versus delayed invasive strategy for intermediate- and high-risk acute coronary syndromes managed without P2Y₁₂ receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial.

ABSTRACT: According to recent literature, pretreatment with a P2Y₁₂ ADP receptor antagonist before coronary angiography appears no longer suitable in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) due to an unfavorable risk-benefit ratio. Optimal delay of the invasive strategy in this specific context is unknown. We hypothesize that without P2Y₁₂ ADP receptor antagonist pretreatment, a very early invasive strategy may be beneficial. The EARLY trial (Early or Delayed Revascularization for Intermediate- and High-Risk Non-ST-Segment Elevation Acute Coronary Syndromes?) is a prospective, multicenter, randomized, controlled, open-label, 2-parallel-group study that plans to enroll 740 patients. Patients are eligible if the diagnosis of intermediate- or high-risk NSTE-ACS

SUBMITTER: Lemesle G

PROVIDER: S-EPMC6490048 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Early versus delayed invasive strategy for intermediate- and high-risk acute coronary syndromes managed without P2Y₁₂ receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Early versus delayed invasive strategy for intermediate- and high-risk acute coronary syndromes managed without P2Y12 receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Early versus delayed invasive strategy for intermediate- and high-risk acute coronary syndromes managed without P2Y₁₂ receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial.